Xencor Shares Rise 33% After Early-Stage Kidney Cancer Trial Data
Xencor said its treatment for certain forms of kidney cancer showed “impressive antitumor activity” in a recent early-stage trial. Shares rose 33% to $33.56 in premarket trading Monday.
Story updates
10:47:08 AM UTC
SquawkNews
06:47 AM EDT, 10/26/2026 (MT Newswires) -- Xencor (XNCR) stock jumped 25% during Monday premarket tr
By Connor HartShares of Xencor climbed after the company said its treatment for certain forms of kidney cancer demonstrated "impressive antitumor activity" during a recent early-stage trial.The stock rose 33% to $33.56 in premarket trading Monday. Through Friday's close, shares are up nearly 65% ye…